December 2, 2020
Business News

Arixa Pharmaceuticals Announces Acquisition by Pfizer’s Hospital Business


PALO ALTO, Calif.–()–Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer’s Hospital Business has agreed to acquire Arixa.

Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz® (sold by Pfizer as Zaficefta® outside the United States), an intravenous-only combination with ceftazidime for the treatment of a number of indications caused by Gram-negative pathogens. Arixa Co-Founder and CSO Dr. Eric M. Gordon led a team to address the challenge of creating a viable prodrug of avibactam with…



Click here to view the original article.

Related Posts

You might also like ...

The Access Group acquires Abintegro Ltd to Extend Capabilities in Career Development and Human Capital Management
Groupe PSA to Launch All-electric Versions of Its Compact Van in 2021
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products